Analyst Price Targets — INVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2026 12:06 pm | — | BTIG | $42.00 | $23.49 | TheFly | Innoviva price target raised to $42 from $35 at BTIG |
| February 26, 2026 2:24 pm | Steve Seedhouse | Cantor Fitzgerald | $32.00 | $23.98 | StreetInsider | Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook |
| February 17, 2026 11:10 am | — | BTIG | $35.00 | $22.70 | TheFly | Innoviva initiated with a Buy at BTIG |
| December 16, 2025 11:11 am | — | H.C. Wainwright | $46.00 | $20.15 | TheFly | Innoviva price target raised to $46 from $45 at H.C. Wainwright |
| September 30, 2025 9:12 am | — | Goldman Sachs | $17.00 | $19.03 | TheFly | Innoviva initiated with a Sell at Goldman Sachs |
| August 11, 2025 11:53 am | Trevor Allred | Oppenheimer | $35.00 | $19.93 | Benzinga | This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday |
| March 7, 2025 12:00 pm | — | Scotiabank | $55.00 | $17.64 | TheFly | Innoviva initiated with an Outperform at Scotiabank |
| August 8, 2022 9:38 am | — | Morgan Stanley | $13.00 | $14.72 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $13 |
| July 15, 2022 11:05 am | — | Morgan Stanley | $12.00 | $14.37 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $12 |
Latest News for INVA
Nortiva Bio, Inc. (âNortivaâ) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines u
LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can…
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in…
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INVA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.